CytomX Therapeutics
CTMX
179 hedge funds and large institutions have $908M invested in CytomX Therapeutics in 2026 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 59 increasing their positions, 28 reducing their positions, and 19 closing their positions.
305% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 19
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
111% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 28
48% more capital invested
Capital invested by funds: $614M → $908M (+$294M)
47% more funds holding
Funds holding: 122 → 179 (+57)
28.46% more ownership
Funds ownership: 85.05% → 113.5% (+28%)
5% more call options, than puts
Call options by funds: $13.3M | Put options by funds: $12.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$47.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.9M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$30.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$25.7M |
| 5 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$22.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$32.8M |
| 2 |
VA
VR Adviser
New York
|
-$28.3M |
| 3 |
Financial Engines Advisors
Santa Clara,
California
|
-$16.3M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.9M |
| 5 |
O
OrbiMed
New York
|
-$15M |
CTMX Hedge Fund Activity: Q1 2026 in Review
179 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2026, worth a combined $908M — up 48% from $614M a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new CTMX positions and 19 closed out — a net gain of 58 holders — while 59 added to existing stakes and 28 trimmed.
The largest buyer was Bank of America, adding an estimated $47.3M. The largest seller was Commodore Capital, exiting entirely with an estimated $32.8M sold.
- 179 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2026, up from 122 in Q4 2025.
- Funds reported $908M of CytomX Therapeutics stock for Q1 2026, up 48% quarter-over-quarter.
- 77 funds opened new CytomX Therapeutics positions in Q1 2026 and 19 closed out, a net change of +58 holders.
- The largest CytomX Therapeutics buyer in Q1 2026 was Bank of America, an estimated $47.3M added.
- The largest CytomX Therapeutics seller in Q1 2026 was Commodore Capital, an estimated $32.8M sold.
Based on aggregated 13F filings for Q1 2026.